^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

Excerpt:
Low pIL6 at baseline was significantly associated with improved response to sunitinib (Fisher's exact test, p < 0.01)…. low pIL6 at baseline was significantly associated with improved PFS (log rank,  = 0.04 …Forty-six patients with metastatic or non-resectable ccRCC treated with sunitinib...
DOI:
10.1016/j.ctarc.2019.100127